Inhibition of monocyte chemoattractant peptide-1 decreases secondary spinal cord injury

Introduction

Spinal cord injury (SCI) is a serious complication of vertebral fractures. Primary SCI, caused by vertebral fracture, results in an irreversible mechanical injury to the spinal cord (1). Secondary SCI is often a sequel to the primary injury that results from arterial disruption, electrolyte imbalance, thrombosis or hypoperfusion due to shock. Secondary SCI is associated with complex pathological and physiological processes that have widespread consequences. For this reason, secondary SCI may be more harmful to the nervous system than the primary injury.

Secondary SCI is both preventable and reversible. Physical therapy and the early application of drug therapy can have a significant impact on patient prognosis. However, to date, therapeutic options for secondary SCI management are limited and the development of clinical and therapeutic modalities based on new technology is the subject of ongoing research (2).

The roles of apoptosis and necrosis in secondary SCI have been reported previously (2). Neuronal and glial cell death does not appear to be due to direct damage. Studies using animal models and human tissue samples have revealed that cell damage is associated with the apoptosis of neuronal and glial cells, and that these processes may be key factors in secondary SCI (3,4).

The extent of apoptosis and cavity formation in the spinal cord after secondary SCI are important factors that require further investigation. These changes have been shown to decrease when hemorrhaging is reduced by drug treatment (5). Other research has demonstrated that inflammation occurs following secondary SCI, leading to the abnormal apoptosis of neuronal and glial cells, thereby exacerbating the situation.

Increases in the mRNA levels of the cytokine factor monocyte chemoattractant peptide-1 (MCP-1) have been observed following the occurrence of secondary SCI (6). This finding may shed light on the mechanism that precipitates tissue inflammation (7).

In the present study, an astrocyte cell line from rat brain tissue and a rat model of Nyström’s posterior spinal cord compression injury were used to explore the association between MCP-1 expression and secondary SCI.

Materials and methods

Cell culture

Whole brains harvested from newborn rats under sterile conditions were placed in D-Hank’s solution containing 10% fetal bovine serum and 5% DMEM-F12 (Gibco, Carlsbad, CA, USA). The pallium was separated under a dissecting microscope and the resulting tissue was exposed to trypsin. Cells were collected by centrifugation and plated onto Petri dishes at a density of 1.5×107 cells per dish. The cells were cultured for 10 days at 37°C in the presence of 5% CO2 and 95% O2. High purity astrocytes were prepared following separation, purification and subculture.

Animal models

Healthy, closed population, male Sprague-Dawley (SD) rats weighing 260–300 g were used for the animal models. The rats were given free access to food and water in natural light at room temperature. Improved Nyström surgery was performed in order to produce the spinal cord injury by applying compression for 5 min with a 35-g weight. Following surgery, the rats were raised separately at room temperature. In the control group, the lamina of the vertebral arch was removed to expose the dura mater. A total of 80 SD rats were used to establish the animal model. In total, 20 rats died; four during the breeding period, six during anesthesia for surgery and ten during the observation period once the model had been established. The 60 surviving rats were randomly divided into five groups, with 12 rats in each group; group 1 (untreated group), group 2 (sham surgery group), group 3 (rat spinal cord compressed for 1 min), group 4 (rat spinal cord compressed for 5 min) and group 5 (rat spinal cord compressed for 10 min). All animal studies were approved by the Institutional Animal Care and Use Committee of the Second Military Medical University (Shanghai, China) and all experimental procedures were carried out in accordance with institutional guidelines.

RNA manipulation studies

A small interfering RNA expression vector, pSilencer 3.1-H1 puro (Ambion, Foster City, CA, USA) containing MCP-1 and MCP-1β targeting sequences, and appropriate scrambled controls were constructed according to the manufacturer’s instructions. In order to select the optimum targeting sequences, the MCP-1 coding sequences were submitted to the Ambion siRNA target finder website (http://www.ambion.de/en/) for prediction. The following two small interfering (siRNA) sequences and a scramble siRNA, as a negative siRNA control, were used for the RNA interference experiments: MCP-1, 5′-GAT CCC GTGCCCCACTCACCT GCTGCT TCA AGA GAG CAGC AGG TGA GTG GGG CAC TTT TTT GGA AA-3′ and 5′-AGC TTT TCC AAA AAA GTG CCC CAC TCA CCT GCTG CTC TCT TGA AGC AGC AGGTGAGTGGGGCACGG-3′; and scramble siRNA, 5′-ATGGACAGAATAAATGGACTT-3′. Constructed pSilencer-MCP-1 and pSilencer-MCP-1β were transfected into the astrocyte cell line using Lipofectin (Invitrogen, Carlsbad, CA, USA).

Protein and mRNA quantification

Changes in the expression of MCP-1 and MCP-1β were confirmed by the measurement of mRNA and protein levels. Total RNA was extracted from cell line samples using TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. Reverse transcription polymerase chain reaction (RT-PCR) was used to evaluate the mRNA expression levels. The primers used were as follows (100 nM each): MIP-1β upstream, 5′-TCTGCGATTCAGTGCTGTCAGC-3′ and downstream, 5′-GATTTGCCTGCCTTTTTTGGTC-3′; MCP-1 upstream, 5′-CCTGTTGTTCACAGTTGCTGCC-3′ and downstream, 5′-TCTACAGAAGTGCTTGAGGTGGTTG-3′; and β-actin upstream, 5′-ATGGTGGGTATGGGTCAGAA-3′ and downstream, 5′-GCTGTGGTGGTGAAGCTGTA-3′. Cell extracts were prepared in NP-40 lysis buffer (0.1% NP-40, 150 mM NaCl, 1 mM EDTA, 50 mM Tris pH 8.0, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride) supplemented with a protease inhibitor cocktail (Sigma, St. Louis, MO, USA; P-8340). Protein concentrations were determined using a Bradford assay (Bio-Rad, Hercules, CA, USA). Equivalent amounts of protein (10–30 μg) were electrophoretically resolved using SDS-PAGE on 6–10% gels. MCP-1 and MCP-1β primary antibodies were used for western blotting to detect the protein expression levels.

Immunohistochemistry

The astrocyte cell line and rat tissues were subjected to immunohistochemistry. Paraffin-embedded sections were cleared and incubated at 37°C for 10 min with 0.1% Pronase (Roche, Mannheim, Germany; #165 921) in 0.1% CaCl2 at pH 7.8. The suspension was blocked by exposure to 3% hydrogen peroxide in TBST for 10 min. The tissues were further washed and blocked with a biotin blocking system (Dako, Carpinteria, CA, USA; X0590), followed by washing and exposure to 10% normal rabbit serum for 10 min at room temperature. The cells were then incubated for 1 h at room temperature with polyclonal rabbit anti-mouse MCP-1 antibody (1:800 diluted; Santa Cruz Biotechnology, Inc., Dallas, TX, USA). This was followed by incubation for 30 min at room temperature with biotinylated rabbit anti-mouse serum (1:100 diluted; Dako Denmark A/S, Glostrup, Denmark) and finally by incubation for 30 min at room temperature with Strep-ABC complex (1:100 diluted; Dako Denmark A/S). The sections were developed for 20 min at room temperature using an AEC substrate kit (Vector Lab, Burlingame, CA, USA; SK-4200), counterstained with hematoxylin and, following drying, were mounted with Dako aqueous mount (Dako Denmark A/S).

Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay

TUNEL is a common method for detecting the DNA fragmentation that results from apoptotic signaling cascades. The technique was applied to an astrocyte cell smear and tissue samples using an in situ cell death detection kit (Roche). Cell smear preparation, tissue sample treatment and TUNEL analysis were performed according to the manufacturer’s instructions. Cells were mounted under a glass coverslip and analyzed with a fluorescence microscope to observe apoptosis.

Results and Discussion

RNA inhibition (RNAi) plasmid inhibits MCP-1 expression

MCP-1 plays an important role in the inflammatory response induced by secondary SCI (6,8). RNAi decreased the expression of MCP-1 in animal models and astrocyte cell lines (Figs. 1 and 2). This finding provides a basis for further studies investigating the effect of MCP-1 expression on SCI.

Figure 1 RNAi plasmid inhibits MCP-1 expression in astrocyte cell lines. MCP-1, monocyte chemoattractant peptide-1; RNAi, RNA inhibition.

Figure 2 MCP-1 protein expression is inhibited by RNAi plasmid in astrocyte cell lines and in the rat spinal cord injury model. MCP-1, monocyte chemoattractant peptide-1; RNAi, RNA inhibition.

Inflammatory response after secondary SCI

Astrocytes are a major cell type found in the cerebrum. These cells constitute an inner microenvironment essential for neuron development. They also contain a number of neurotransmitters, which facilitate neuronal conduction. It has been reported that astrocytes in the region of the blood-brain (spinal cord) barrier are involved in inflammatory immune responses in the brain and spinal cord. These cells excrete inflammatory chemokines involved in the recruitment of peripheral blood monocytes, macrophages and T lymphocytes (9–11).

It has previously been demonstrated that an inflammatory response occurs during the first few hours after SCI. This involves activation of the remaining astrocytes and the infiltration of peripheral inflammatory cells; the majority of these are neutrophils, granulocytes, monocytes and macrophages (12). Glial cells and vascular endothelial cells in the central nervous system produce inflammatory cytokines (13).

Changes that occurred at different stages of injury in the rat SCI model are shown in Fig. 3. Sections from the animal model revealed that the most severe SCI occurred after 24 h, where the necrosis of glial cells, a reduction in the number of neurons and disorder of white matter structure with only a few nerve cells remaining around the area of damage were observed. Injured neurons were detected, mainly around small vessels.

Figure 3 Changes at different stages of injury in the rat spinal cord injury (SCI) model. (A) Nissl staining of the damaged area 2 weeks after severe SCI (longitudinal section; magnification, x200). (B) Glial fibrillary acidic protein (GFAP) staining of the damaged area 1 week after mild SCI (longitudinal section; magnification, x200). (C) GFAP staining of the damaged area 24 h after moderate SCI (longitudinal section; magnification, x200); (D) Hematoxylin and eosin (H&E) staining of the damaged area 2 weeks after severe SCI (longitudinal section; magnification, x200). (E) H&E staining of the damaged area 4 h after mild SCI (longitudinal section; magnification, x200). (F) H&E staining of the damaged area 24 h after moderate SCI (transverse section; magnification, x200).

Following 2 weeks of SCI, glial fibers gradually appeared in the grey matter, accompanied by small cystic degeneration. The central canal began to reconstruct, changes in white matter structure were observed and the abundant proliferation of glial cells was detected.

Inhibiting MCP-1 reduces inflammatory changes

Inflammatory cytokines, including IL-1β and TNF-α, are hypothesized to cause the accumulation and increased expression of MCP-1 in rat astrocytes, and these changes may be involved in important signaling pathways (14). In the same experiments, abnormally high expression levels of these cytokines were shown to be correlated with the development of inflammation.

In rat models of cerebral cortical nitrocellulose membrane needle-stick injury, elevated MCP-1 expression has been linked to astrocyte activation and the infiltration of monocytes and macrophages (15). It has been demonstrated that mechanical injury to the central nervous system causes astrocytes to produce MCP-1 (11).

The expression of inflammatory chemokines MCP-1 and MIP-1β were significantly increased in the secondary SCI rat model (Fig. 4), which is consistent with previous studies (6,16).

Figure 4 Change in MCP-1 expression prior to and following the emergence of spinal cord injury in rat models. (A) 24 h after the emergence of spinal cord injury; (B) prior to the emergence of spinal cord injury. MCP-1, monocyte chemoattractant peptide-1.

In this study, MCP-1 and MIP-1β expression increased after SCI and monocyte and macrophage infiltration also increased in the damaged areas. After antisense gene intervention, the expression levels of MCP-1 and MIP-1β were reduced and the infiltration of monocytes and macrophages decreased.

The expression of TNF-α in response to spinal injury decreased after RNAi inhibited the expression of MCP-1 (Fig. 5), demonstrating that the inflammatory response induced by SCI is associated with MCP-1 expression.

Figure 5 At 24 h after secondary spinal cord injury (SCI), TNF-α protein expression was increased compared with the sham-surgery control group. TNF-α expression was reduced, but remained higher than that in the control group, following the inhibition of MCP-1 expression. MCP-1, monocyte chemoattractant peptide-1.

The observation of rat tissue sections revealed that significant changes occurred in the activity of monocytes and macrophages following the inhibition of MCP-1 expression.

Reduction in MCP-1 expression inhibits neural cell apoptosis induced by secondary SCI

Following the emergence of secondary SCI, apoptosis induced by a series of inflammatory responses following the primary SCI resulted in neural cell necrosis. We demonstrated that the number of TUNEL-positive cells reached a peak at 24 h after the primary SCI (Table I). The TUNEL-positive cells were mainly glial cells and were predominantly distributed in grey matter. The number of TUNEL-positive glial cells in the white matter reached a peak ~72 h later. However, in the RNAi group, the number of TUNEL-positive cells in the grey and white matter were lower than the control group following inhibition of MCP-1 expression by RNAi (Table I).

Table I Positive cells at various time-points after spinal cord injury, as determined by a TUNEL assay.

Table I

Positive cells at various time-points after spinal cord injury, as determined by a TUNEL assay.

Time after spinal cord injury	Number of positive cells (mean ± SD)
	Grey matter		White matter
	RNAi	Control	RNAi	Control
1 h	0±1	0±1	0±1	0±1
8 h	40±10	42±8a	7±2	9±1
24 h	10±3	95±12a	6±1	35±5a
72 h	5±3	50±6a	9±4	413±10a

a P<0.05 vs. 1 h after spinal cord injury. TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; RNAi, RNA inhibition.

Apoptosis in secondary SCI is a process in which numerous regulatory factors are involved, with the caspase family as the core component. Low caspase-3 expression is usually detected in the spinal cord nerve cells of normal rats; however, its expression has been found to increase several hours after SCI, reaching a peak after 2–3 days (17). This time profile is consistent with the apoptotic process. Furthermore, it has been observed that caspase-1 activity is inhibited after the emergence of SCI in mice lacking dynorphin, suggesting that caspase-1 protects the nervous tissues following the occurrence of SCI (18).

In the present study, following SCI, caspase-3 expression levels decreased compared with the control group after the inhibition of MCP-1 expression (Fig. 6). Immunohistochemistry revealed that injury to neuronal cells and astrocytes decreased, suggesting that a reduction in MCP-1 expression inhibits the aggravation of apoptosis, thus protecting nerve cells during the secondary SCI process.

Figure 6 Inhibition of MCP-1 expression affects the expression of caspase-3, which attenuates apoptosis, thus protecting the nerve cells after the emergence of spinal cord injury (SCI). MCP-1, monocyte chemoattractant peptide-1.

In conclusion, our results suggest that inhibiting inflammation alleviates nerve cell injury caused by apoptosis and offers an important approach to the future treatment of secondary SCI. The use of RNAi to inhibit MCP-1 expression, alleviate spinal cord injury and protect nerve cells offers a feasible treatment strategy for patients with this condition. Further research is required to investigate the pathogenesis of secondary SCI and to explore the clinical use of RNAi.

Acknowledgments

This study was supported by the Young Science Fund Projects of National Natural Science Fund (no. 30801155). We appreciate the valuable advise from other members of our laboratories.

References